Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Fulcrum Therapeutics, Inc. (FULC) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/22/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation - FTX-6058 for Sickle Cell Disease Program Update",
"Corporate Presentation - FTX-6058 for Sickle Cell Disease Program Update"
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Dee Smith Executive Director, Corporate Communications Fulcrum Therapeutics,"
07/10/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
07/07/2023 SC 13G/A BlackRock Inc. reports a 2.5% stake in FULCRUM THERAPEUTICS INC
06/09/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment of the Restated Certificate of Incorporation of Fulcrum Therapeutics, Inc",
"Certificate of Amendment of the Restated Certificate of Incorporation of Fulcrum Therapeutics, Inc"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Quarterly results
Docs: "Dee Smith Executive Director, Corporate Communications Fulcrum Therapeutics,"
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/05/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Quarterly results
Docs: "Dee Smith Executive Director, Corporate Communications Fulcrum Therapeutics,"
03/06/2023 SC 13G ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 5.6% stake in Fulcrum Therapeutics, Inc.
02/14/2023 SC 13G/A Third Rock Ventures III, L.P. reports a 4.5% stake in Fulcrum Therapeutics, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A FMR LLC reports a 10.1% stake in FULCRUM THERAPEUTICS INC
01/23/2023 SC 13G/A Cowen Financial Products LLC reports a 2.6% stake in Fulcrum Therapeutics Inc.
01/18/2023 8-K Quarterly results
01/18/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
01/17/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
01/17/2023 8-K Quarterly results
01/06/2023 SC 13G/A RA CAPITAL MANAGEMENT, L.P. reports a 18.6% stake in FULCRUM THERAPEUTICS, INC.
01/04/2023 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Fulcrum Therapeutics Provides Business Update and 2023 Outlook",
"Slide from Corporate Presentation"
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
Docs: "Stern Investor Relations, Inc."
10/19/2022 8-K Quarterly results
08/26/2022 SC 13G RA CAPITAL MANAGEMENT, L.P. reports a 13.4% stake in FULCRUM THERAPEUTICS, INC.
08/23/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/16/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy